StreetInsider.com News Articles

Xenon Pharmaceuticals (XENE) PT Raised to $77 at BofA Securities

Thu, 12 Mar 2026 16:40:42 -0400

BofA Securities analyst Jason Gerberry raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $77.00 (from $50.00) while maintaining a Buy rating.

The analyst comments "This morning, Xenon announced positive Ph3 topline results for azetukalnar (AZK) from the X-Tole2 study, which validated a competitive commercial profile (like prior studies) and a data package with a high POS (we move to 100% POS vs prior 80%). While a decision on launch pricing is more likely post-approval, management commentary on optimizing (underpriced) relative to brand reference (Xcopri) leads us to bump our launch pricing (more below), increasing our peak AZK peak sales

Xenon Pharmaceuticals (XENE) PT Raised to $77 at BofA Securities

Thu, 12 Mar 2026 16:40:42 -0400

BofA Securities analyst Jason Gerberry raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $77.00 (from $50.00) while maintaining a Buy rating.

Form 8-K Xenon Pharmaceuticals For: Mar 10

Thu, 12 Mar 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260312/26153430.html

Form 8-K Xenon Pharmaceuticals For: Mar 10

Thu, 12 Mar 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260312/26153430.html

Xenon Pharmaceuticals closes $747.5 million public offering

Thu, 12 Mar 2026 16:01:21 -0400

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) completed its underwritten public offering of common shares and pre-funded warrants, raising approximately $747.5 million in gross proceeds.

The Vancouver and Boston-based biopharmaceutical company sold 12,236,843 common shares at $57.00 per share and pre-funded warrants to purchase up to 877,194 common shares at $56.9999 per warrant. The offering included 1,710,526 shares from the full exercise of underwriters' option to purchase additional shares.

J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair served as joint book-running managers for the offering, while Baird acted as lead manager.

The offering was conducted under a shelf registration statement filed

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Thu, 12 Mar 2026 16:01:00 -0400

VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the closing of its previously announced underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 877,194 common shares. The common shares were offered at a public offering price of $57.00 per common share, and the pre-funded warrants

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Thu, 12 Mar 2026 16:01:00 -0400

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Thu, 12 Mar 2026 16:01:00 -0400

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Thu, 12 Mar 2026 16:01:00 -0400

Form 424B5 Xenon Pharmaceuticals

Thu, 12 Mar 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260312/26148446.html

Form 424B5 Xenon Pharmaceuticals

Thu, 12 Mar 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260312/26148446.html

Form 4 Xenon Pharmaceuticals For: Mar 09 Filed by: DiFabio Andrea

Wed, 11 Mar 2026 19:21:00 -0400

si-local-file:///var/storage/secattach/20260311/26147655.html

Form 4 Xenon Pharmaceuticals For: Mar 09 Filed by: DiFabio Andrea

Wed, 11 Mar 2026 19:21:00 -0400

si-local-file:///var/storage/secattach/20260311/26147655.html

Form 4 Xenon Pharmaceuticals For: Mar 09 Filed by: KENNEY CHRISTOPHER JOHN

Wed, 11 Mar 2026 19:21:00 -0400

si-local-file:///var/storage/secattach/20260311/26147657.html

Form 4 Xenon Pharmaceuticals For: Mar 09 Filed by: KENNEY CHRISTOPHER JOHN

Wed, 11 Mar 2026 19:21:00 -0400

si-local-file:///var/storage/secattach/20260311/26147657.html

Form 4 Xenon Pharmaceuticals For: Mar 09 Filed by: MORTIMER IAN

Wed, 11 Mar 2026 19:20:00 -0400

si-local-file:///var/storage/secattach/20260311/26147652.html

Form 4 Xenon Pharmaceuticals For: Mar 09 Filed by: MORTIMER IAN

Wed, 11 Mar 2026 19:20:00 -0400

si-local-file:///var/storage/secattach/20260311/26147652.html

Form FWP Xenon Pharmaceuticals Filed by: Xenon Pharmaceuticals Inc.

Wed, 11 Mar 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260311/26142168.html

Form FWP Xenon Pharmaceuticals Filed by: Xenon Pharmaceuticals Inc.

Wed, 11 Mar 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260311/26142168.html

Xenon Pharmaceuticals prices $650 million stock offering at $57 per share